Ho
No verificado

Holoclara

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud
18/12/2024
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Holoclara Selects Eosinophilic Esophagitis as its Lead Indication for HC002, a First-in-Class Worm-Derived Therapy
1.00
18/12/2024
Biotecnología
Salud
Medicina - Varios
Industria
Holoclara Initiates Phase 1 Clinical Trial Evaluating Worm-Derived Therapeutic HC002 in Healthy Adults
1.00
27/06/2024
Ciencia
VIH, SIDA y enfermedades autoinmunes
Higiene alimentaria
Biotecnología
Salud
Farmacéutica
Sanidad
Holoclara Announces $16 Million Series A Financing to Advance a Breakthrough Class of Worm-Derived Therapies for Allergic and Autoimmune Disease
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0